ERBB2 and neoplasm: Thus, IHC 3+ tumours had higher rates of pCR than IHC 2+/HER2 amplified tumours, when either in receipt of chemotherapy alone (37.5% versus 12.5%; p = 0.22) or anti-HER2 therapy (51.8% versus 20.3%; p < 0.001).